AbbVie advances cosmetic indication for jawline contouring as regulatory pathway accelerates.
The FDA has accepted AbbVie's supplemental Biologics License Application (sBLA) for BOTOX in masseter hypertrophy—the cosmetic indication for jawline prominence reduction. The acceptance signals the agency's preliminary view that the application is complete and substantively reviewable, clearing a key regulatory hurdle.
Masseter BOTOX represents a meaningful expansion of the toxin's cosmetic label and a direct competitive response to Revance's Daxxify, which already carries the indication. The masseter market—driven by younger demographics and aesthetic demand for facial contouring—has grown faster than traditional glabellar and lateral canthal uses, and label approval will likely accelerate adoption among practices seeking new revenue streams.
FDA accepts BOTOX masseter sBLA; approval clears regulatory path.
Practice owners should monitor the approval timeline and label language closely. If approved, the indication will require patient education and dosing precision (masseter injections typically demand 20–50 units per side, higher than brow work), and reimbursement coding will matter for any medical necessity claims in jaw-clenching or TMJ-related cases.
Source: original report ↗
Frequently asked questions
When will BOTOX be approved for masseter jawline contouring?
The FDA has accepted AbbVie's supplemental Biologics License Application (sBLA) for masseter BOTOX, meaning the agency views the application as complete and reviewable. No specific approval date has been announced, but acceptance clears a major regulatory hurdle and signals the pathway is moving forward.
How many units of BOTOX are needed for masseter injections?
Masseter injections typically require 20–50 units per side, which is significantly higher than traditional brow or canthal work. Practices will need to train staff on proper dosing precision once the indication is approved.
Is BOTOX already approved for jawline contouring?
No, but Revance's Daxxify already carries the masseter hypertrophy indication. BOTOX's approval is pending and represents AbbVie's competitive response to capture this faster-growing cosmetic segment.
What is the masseter BOTOX market opportunity for med spas?
The masseter market is driven by younger demographics seeking facial contouring and has grown faster than traditional glabellar and canthal uses. Label approval will likely accelerate adoption among practices looking to add new revenue streams.
Can BOTOX for masseter be billed as medically necessary?
Potentially, for jaw-clenching or TMJ-related cases, but reimbursement coding will be critical and will depend on final label language and payer policies. Practice owners should monitor the approved indication closely for any medical necessity claims.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
